Follicular Lymphoma

Compared with remdesivir and molnupiravir, ensitrelvir achieves higher rates of SARS-CoV-2 antigen clearance and a more favorable viral shedding profile. Case Presentation: A 67-year-old Japanese man with follicular lymphoma had received obinutuzumab plus bendamustine, followed by obinutuzumab maintenance therapy...Three months prior to the current admission, the patient developed coronavirus disease 2019 (COVID-19) and was treated with a 10-day course of remdesivir and dexamethasone... Ensitrelvir may be an effective therapeutic option for the treatment of persistent or refractory COVID-19 in immunocompromised patients. Clinicians should recognize that patients treated with obinutuzumab may remain immunosuppressed for several years after therapy.

In tissue from a case of marginal zone lymphoma, high TNFR2 expression was found on CD4+ and CD8+ T cells, B cells, and monocytes but also directly on tumor cells. We conclude sTNRF2 is a strong prognostic biomarker of OS across major lymphoma subtypes and may be useful to guide therapeutic choices, including targeted therapies against immunosuppressive TNFR2-expressing Tregs.

P1, N=135, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=225 --> 135

Both current classifications recognize some categories of BCL2-R negative FL including the "predominantly diffuse FL" (WHO-HAEM5) (overlapping with the "BCL2-R negative/CD23 positive follicle center lymphoma" according to the ICC) often presenting in the inguinal region with an indolent course; the paediatric-type FL and the testicular FL affecting children or young adults. The recently described "follicle center lymphoma of the lower female genital tract" shows some similarities with primary cutaneous follicle center lymphoma.

P1, N=224, Active, not recruiting, C4 Therapeutics, Inc. | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Sep 2026

Here, we show that combining the PI3Kδ inhibitor linperlisib with the pan-peroxisome proliferator-activated receptor (PPAR) agonist chiglitazar, an agent that reprograms tumor metabolism, delivers robust antitumor activity across FL models, including cell-derived and patient-derived xenografts, with a favorable tolerability profile. Compared with monotherapy, the combination consistently achieves superior tumor control in vivo without overt toxicity, supporting its clinical translation potential. Collectively, these data provide a mechanistic rationale for dual targeting of PI3Kδ and PPARα in FL and advocate for clinical evaluation of this combination with FoxO1 as a pharmacodynamic biomarker.

P1, N=20, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting

P3, N=331, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

P1/2, N=47, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Mar 2026 --> Mar 2028 | Trial completion date: Mar 2026 --> Mar 2028

P1, N=248, Recruiting, Nurix Therapeutics, Inc. | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2026

P3, N=420, Recruiting, AstraZeneca

P1/2, N=253, Active, not recruiting, Taiho Oncology, Inc. | Trial completion date: Dec 2025 --> Dec 2027